This section is sponsored in part by:  
|
Research on HIV Drug Resistance
Overviews
- News on HIV Drug Resistance in New Antiretrovirals From the XVI International HIV Drug Resistance Workshop (July 24, 2007)
With every new medication it's critical to understand which mutations are predictive of a less than optimal response. In this report on Doug Richman's review from the XVI International HIV Drug Resistance Workshop, Mark Holodniy, M.D., discusses genotypic and phenotypic assays associated with R5 inhibitors and HIV drug resistance associated with the following antiretrovirals in development: etravirine, raltegravir, elvitegravir and maraviroc.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- New Developments in the Management of HIV Treatment-Naive Patients (February 28, 2007)
Includes an analysis of research examining once-daily regimens, the use of viral decay rate to assess treatment efficacy, and issues related to primary HIV drug resistance.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline NNRTI Resistance and Virologic Failure in Treatment-Naive Patients on Efavirenz: An Interview With Daniel Kuritzkes, M.D. (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Optimizing Therapy for Patients With Multidrug-Resistant HIV (July 31, 2006)
To read PDF, click here
From Insight Medical Communications Inc.
- Survey Reveals Nearly Twice as Many Physicians Than Patients Are Concerned About HIV Drug Resistance (July 18, 2006)
From American Academy of HIV Medicine
- New Developments in HIV Drug Resistance and Options for Treatment-Experienced Patients (May 15, 2006)
Coverage of the 4th European HIV Drug Resistance Workshop and the 12th Annual Conference of the British HIV Association
Free CME/CE credit available for physicians, nurses and pharmacists.
From The Body PRO
- Wall Street Journal Spotlights HIVers With Heavy Drug Resistance (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Conference Presentation Provides Overview of Some Drug Resistance Assays (July 25, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- The Link Between Unsafe Sex, Poor HAART Adherence, Resistance and Drug Resistant HIV Transmission (July 25, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- HIV Drug Resistance Notes: Resistance Levels Conferred by Key Mutations (December 2004)
A class-by-class chart of drug resistance associated with specific HIV gene mutations, adapted from the Stanford HIV Drug Resistance Database.
To read PDF, click here
In Infectious Diseases in Corrections Report, from Brown Medical School
- Overview of ICAAC 2004 Research on HIV Drug Resistance (November 2004)
Mark Mascolini on the transmission of drug-resistant HIV, the lack of a tie between resistance and viral load "blips," the existence of a tie between resistance and persistently detectable viral load, and the significance of the K65R mutation.
From National AIDS Treatment Advocacy Project
- Reduced Drug Susceptibility Found Among 23% of Treatment-Naive Patients (October 31, 2004)
Reduced susceptibility to the NNRTI class was found to be most common; phenotypic resistance was most likely among white patients.
From aidsmap.com
- New Insight Into HIV Drug Resistance (September 2004)
In this summarized talk, Daniel R. Kuritzkes, M.D., discusses the latest, most significant findings.
In The PRN Notebook
- Resistance Reshufflings: Highlights of the XIII International HIV Drug Resistance Workshop (August 2004)
Summaries of a wide range of data presented at Tenerife, Canary Islands, from June 8-12, 2004.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Rapid Report: XIII International HIV Drug Resistance Workshop (PDF) (June 30, 2004)
A detailed workshop summary by Marc Mascolini; this conference took place from June 8-12, 2004, in the Canary Islands.
From Informed Horizons
- Report from the XIII International Workshop on HIV Drug Resistance (June 2004)
By David Margolis, M.D.; this conference took place from June 8-12, 2004, in the Canary Islands.
From National AIDS Treatment Advocacy Project
- Update on the Treatment of Acute and Early HIV Infection (May 2004)
Details of a talk by Dr. Martin Markowitz of the Aaron Diamond AIDS Research Center and Dr. Bruce Walker of Harvard Medical School; includes a discussion of drug resistance transmission.
In The PRN Notebook
- 2nd European HIV Drug Resistance Workshop: Slide Presentations (March 11-13, 2004)
From HIVpresentation.com
- 2nd European HIV Drug Resistance Workshop: Study Abstracts (March 11-13, 2004)
From HIVpresentation.com
- Highlights of the 2nd European HIV Drug Resistance Workshop (PDF) (March 11-13, 2004)
In Virology Education
- Mechanisms of HIV Drug Resistance: A Primer (March 2004)
In The PRN Notebook
- Adherence and HIV Drug Resistance (January 2004)
"Near-perfect" adherence to a powerful HAART regimen appears to be the best way to avoid developing drug-resistant HIV.
In Hopkins HIV Report
- Importance of Resistance Testing and Therapeutic Drug Monitoring for Treatment Success (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Managing Patients After Virologic Failure (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Transmission of Drug-Resistant HIV (September 2003)
A review of recent research on the spread of HIV drug resistance, and what impact it might have on HIV treatment in the future.
In The PRN Notebook
- Clinical Use of Drug Resistance Testing (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Questions to and Answers From the International AIDS Society-USA Resistance Testing Guidelines Panel (PDF) (July/August 2003)
Twenty questions about drug resistance addressed by top medical experts.
In Topics in HIV Medicine
- Understanding Treatment-Resistant HIV (June 2003)
A detailed clinical report on the transmission of resistant HIV, resistance tests, hypersusceptibility and resistance data on new antiretrovirals.
In The PRN Notebook
- Is Transmitted Drug Resistance in HIV on the Rise? It Seems So (May 5, 2001)
In British Medical Journal
- Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness (March 20, 2001)
In The Annals of Internal Medicine
- HIV Drug Resistance and Drug-Resistance Testing (March 2001)
To read PDF, click here
In The PRN Notebook
HIV Mutations
- HIV Resistance Response Database Initiative (Regularly Updated)
An international nonprofit database of HIV drug mutations.
- National Cancer Institute HIV Drug Resistance Program (Regularly Updated)
This program organizes and conducts research and symposia on HIV drug resistance.
- Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- How the HIV-1 Reverse Transcriptase Mutations K65R, M184V and K65R + M184V Produce Resistance to NRTIs (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Phenotypic Clinical Cutoffs for Tipranavir/Ritonavir Defined Based on RESIST Data (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Rise in NRTI Mutations Is Associated With Rise in NNRTI, Protease Inhibitor Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Sustained Virological Response Still Seen in Treatment-Experienced Patients With K65R and Other Resistance Mutations (August 17, 2006)
In XVI International AIDS Conference
- Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Analyzing the Pattern of Resistance Mutation Emergence of a Failing Abacavir + Lamivudine + Tenofovir Regimen Reveals a Possible Compensatory Mutation (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Rare Case of Protease Inhibitor Resistance After Failure of First-Line Boosted Fosamprenavir (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Researchers Uncover Possible Alternative Pathway to Tenofovir Resistance (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Update of the Drug Resistance Mutations in HIV-1: 2005 (PDF) (March/April 2005)
From International AIDS Society Drug Resistance Mutations Group
- K65R Mutation Revealed in 4 Non-Responders to Abacavir + Lamivudine + Tenofovir Failed Regimen -- Significance Unclear (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Is 80%-90% Adherence the Best Predictor of Drug Failure? (February/March 2005)
A study suggests that resistance risk is highest for people who have good, but not great, treatment adherence.
From The Body PRO
- Stable Viral Load but Evolving Drug Resistance (January 2005)
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO
- The Risk of NNRTI Resistance Following Perinatal Nevirapine and Ramifications for Subsequent Antiretroviral Therapy Success (January 2005)
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO
- Single-Dose Drugs May Be Effective, But They Can Jeopardize Long-Term Therapy (November/December 2004)
Recent studies bring potentially bad news for HIV drugs with long half-lives.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- HIV JournalView: Prevalence, Incidence and Predictors of K65R (October 2004)
From The Body PRO
- Viral Load Between 400 and 20,000 Can Still Maintain Patient Health (September 7, 2004)
Partially suppressive HAART appears to protect against death and illness as well as fully suppressive HAART.
From aidsmap.com
- HIV JournalView: Primary Drug Resistance Can Persist a Year or More (September 2004)
From The Body PRO
- HIV JournalView: Stable Viral Load but Evolving Drug Resistance (August 2004)
Analysis of a study published in the journal AIDS.
From The Body PRO
- NNRTI Resistance Occurs More Often at Lower Levels of Adherence Than Does PI Resistance (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
- Intermittent Drug Switching Can Resensitize Patients With Multidrug-Resistant HIV-1 (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO
- NNRTI Not Working? It May Be Safe to Stop It, One Study Suggests (June 28, 2004)
If a patient has become resistant to the NNRTI in a HAART combination, cutting the NNRTI out of the regimen appears to do no additional harm.
From aidsmap.com
- Drug Resistance in Treatment-Naive Patients Only Briefly Impacts CD4 Counts (June 22, 2004)
From aidsmap.com
- Genotyping, Web-Based Program Select Rescue Regimens for HIV-Infected Children (June 15, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- NNRTI Resistance Can Occur in the Absence of Known Mutations (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Resistance Still Possible Despite Perfect Adherence, Study Says (August 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Treatment Interruption Shows No Benefit in Drug-Resistant HIV Infection (August 27, 2003)
From U.S. National Institute of Allergy and Infectious Diseases
- Japan: Doctors Say Drug-Resistant HIV on Rise (August 7, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Low-Level Resistance and Minority Populations: Cross-Resistance Between Nevirapine and Efavirenz (August/September 2003)
Once an NNRTI-based regimen fails, no other NNRTIs will work any better, two studies suggest.
In Treatment Bulletin, from HIV i-Base
- Drug-Resistant HIV Strains Found in One Out of Every 10 Newly Infected European Patients (July 16, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Is Trizivir Plus Tenofovir Effective in Patients With Possible or Proven Reverse Transcriptase Resistance? (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Decreased Replication Capacity of HIV-1 Clinical Isolates Containing K65R or M184V RT Mutations (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Effect of Amprenavir Hypersusceptibility on the Response to APV/Ritonavir-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prevalence of Mutations Associated With Resistance to Antiretroviral Therapy From 1999-2002 (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiretroviral Resistance Among Patients With Primary HIV Infection in the Southeastern U.S. -- Impact on Treatment Outcome (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline Phenotypic Susceptibility to Tipranavir/Ritonavir Is Retained in Isolates From Patients With Multiple Protease Inhibitor Experience (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Comparative Incidence and Temporal Accumulation of PI and NRTI Resistance in HIV-Infected Subjects Receiving Lopinavir/Ritonavir or Nelfinavir as Initial Therapy (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- NEFA Simplification Trial: Genotypic and Phenotypic Resistance Patterns Among Patients With Virological Failure (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Cell Cycles, HIV Drugs and Treatment (January 2003)
Research from the 2002 International AIDS Conference.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Viral Adaptation to Nelfinavir (January/February 2003)
The first reported evidence of drug-dependent enhancement of HIV replication.
In TAGline, from Treatment Action Group
- The Development of K65R Versus Thymidine Analogue-Associated Mutations in Antiviral-Treated Patients (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Shift in HIV-1 Resistance After Treatment Interruption in Patients With Virological Failure and Antiviral Effect Following Trizivir Plus Efavirenz (AZLF3003 Study) (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Data From the 14th International AIDS Conference: Resistance Challenge (October 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Drug Resistance and the Treatment of Experienced Patients (September 2002)
A report from the International AIDS Conference.
In Hopkins HIV Report
- Expert Opinion From Barcelona: Resistance: What Have We Learned? (September/October 2002)
In Positively Aware, from Test Positive Aware Network
- HIV Resistance Meeting Highlights (Fall 2002)
In STEP Perspective, from Seattle Treatment Education Project
- Digging Deeper at the Resistance Workshop (August 14, 2002)
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society
- Antiretroviral-Drug Resistance Among Patients Recently Infected With HIV (August 8, 2002)
Greater primary resistance necessitates earlier drug-resistance testing, researchers say.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons (July 29, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Genotypic and Virtual Phenotypic Correlates of Virologic Response to Abacavir-Based Therapy in the ZORRO Trial (ESS40009) (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Strategies to Prevent Loss of CD4+ and Onset of Resistance During Treatment Interruptions (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
- High Incidence of Primary NNRTI Mutations and M184V in Isolates From Therapy-Experienced Adults Entering the ZORRO Trial (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Prevalence of Genotypic Drug Resistance in HIV-Infected Individuals in New York State: The Resistance Study (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- HIV Drug Resistance Mutations (PDF) (May/June 2002)
Updated figures representing the latest in antiretroviral resistance research.
From International AIDS Society
- Studies of PI-Resistant Virus Offer Tantalizing Possibilities for Immune Reconstitution (May 2002)
"The 1,500 copy cut-off".
In TAGline, from Treatment Action Group
- The Buzz: The Disconnect Syndrome -- A Controversial Dilemma (May/June 2002)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- New Insights Into Mechanisms of HIV-1 Resistance to Reverse Transcriptase Inhibitors (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Treatment of Patients With Drug-Resistant Virus (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Molecular Mechanism of I50V, I54L and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- P-Glycoprotein and HIV (January 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- The Genetic Edge: Fighting Drug Resistance in a Protein's Genes (January 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- HIV Resistance: Data and Spin (December 28, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
- Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Impact of M184V/I Mutation on HIV Phenotypic Resistance to Nucleoside Analogs in NRTI-Experienced Patients (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Impact on Fitness Conferred by Amprenavir Resistance Mutations (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- The Prevalence of Antiretroviral Drug Resistance in the U.S. (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors and Antiretroviral History Do Not Affect Virologic Response to T-1249 (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Comparison of Nevirapine Resistance Mutations in Women vs. Infants Receiving Single Dose NVP Prophylaxis to Prevent HIV-1 Vertical Transmission (HIVNET 012) (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- New Zidovudine-Resistant HIV Found in Treatment-Naive Patients (December 2001)
In HEPP News, from Brown Medical School
- Viral Load: Small Change by Sixth Day of Treatment Can Often Predict Poor Response (November 23, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
- New Finding May Help Doctors Prevent HIV Drug Resistance (November 22, 2001)
From U.S. National Institute of Allergy and Infectious Diseases
- Viral "Blips" May Not Indicate Treatment Failure (November 2001)
In OUTReach, from San Francisco AIDS Foundation
- Predicting the Unpredictable: The Transmission of Drug-Resistant HIV (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Relationship Between Prior Antiretroviral Therapy and Genotypic Testing Among a Large Cohort of HIV-1 Isolates (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Researchers Predict That 42 Percent of HIV in San Francisco Will Be Drug-Resistant by 2005 (September 4, 2001)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Resistance Testing: A Look at the Data (Fall 2001)
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
- HIV Resistance Meeting Web Reports (July 13, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
- Comparison of Drug Susceptibility in HIV-1 From Antiretroviral-Experienced Subjects as Assessed by the Antivirogram and PhenoSense Assays (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Genetic Correlates of Phenotypic Hypersusceptibility to Efavirenz (EFV) in Highly Nucleoside-Experienced Subjects in ACTG 364 (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Prevalence of Phenotypic Resistance to Amprenavir in Protease-Inhibitor-Experienced Patients: Data from CNAB3008 (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- New Antiretrovirals Host Immunology, Pathogenesis and Dynamics Mechanisms of HIV-Drug Resistance Drug Resistance, Exposure and Treatment Response Genotype/Phenotype Relationship, Modelling and Algorithms (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Primary Genotypic and Phenotypic HIV-1 Drug Resistance in Recent Seroconverters in Madrid (July 2001)
In Body Positive, from Body Positive
- Is Transmitted Drug Resistance in HIV on the Rise? It Seems So (May 5, 2001)
In British Medical Journal
- Antiretroviral Resistance Mutations (April 2001)
A collaborative effort of the International AIDS Society-USA Resistance Testing Panel and HIV InSite.
- HIV Drug Resistance and Drug-Resistance Testing (March 2001)
To read PDF, click here
In The PRN Notebook
- A Controlled Phase II Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Low-Dose Ritonavir and Efavirenz in Non-Nucleoside-Naive Protease-Inhibitor-Experienced HIV-1 Infected Adults (February 8, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Prospective, Randomized Study on the Usefulness of Genotypic Resistance Testing and the Assessment of Patient-Reported Adherence in Unselected Patients Failing Potent HIV Therapy (ARGENTA): Final 6-Month Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiretroviral Intensification Accelerates the Decay of the Latent Reservoir of HIV-1 and Decreases but Does Not Eliminate Ongoing Virus Replication (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Genotypic Resistance at Baseline Fails to Predict Outcome Among Chronically Infected, Antiretroviral-Therapy-Naive Patients in Two Large Trials of PI-Based Regimens (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Phenotypic Susceptibility and Virologic Responses in Nucleoside Reverse Transcriptase Inhibitor-Experienced Subjects Receiving NRTIs + Efavirenz (EFV), Nelfinavir (NFV), or Both in ACTG 364 (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Plasma Trough Levels Correlate with Distinct Genetic Mechanisms During the Development of Amprenavir Resistance (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prevalence of Drug-Resistant HIV-1 Variants in Newly Infected Individuals During 1999-2000 (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Time to Appearance of NRTI-Associated Mutations and Response to Subsequent Therapy for Patients on Failing ABC/COM (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Viral Resistance Results From the International, Multicenter, Randomized, Placebo-Controlled, 48-Week Study of Hydroxyurea or Placebo Combined With Efavirenz, Didanosine and Stavudine in Treatment-Naive and -Experienced Patients (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Virologic Suppression From Different Thymidine Analogue-Containing HAART Regimen Sequencing Strategies: VIRA 3001 (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Determination of a Clinically Relevant Phenotypic Resistance "Cutoff" for Abacavir Using the PhenoSense Assay (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- DPC 681 and DPC 684: Resistance and Cross-Resistance Profiles of Second Generation HIV Protease Inhibitors (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Case Management: Michael T., a Longterm Survivor Who Is Failing His Fifth Salvage Regimen (February 2001)
In HIV Newsline, from San Francisco General Hospital
- Superinfection (Reinfection): New Study in San Francisco Offers Free Resistance and Viral Load Testing (December 1, 2000)
In AIDS Treatment News, from AIDS Treatment News
- Novel Aspects of Resistance to Antiretroviral Agents (September 2000)
In The 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Report From the 4th International Workshop on HIV Drug Resistance and Treatment Strategies (September 2000)
In Research Initiative/Treatment Action!, from The Center for AIDS
- AZT and d4T Cross-Resistance (August 8, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Using Resistance Data to Make Treatment Decisions (August 8, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Phenotypic Resistance Testing Significantly Improves Response to Therapy: A Randomized Trial (VIRA3001) (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO
- The Atlantic Study: A Randomized, Open-Label Trial Comparing Two Protease Inhibitor-Sparing Antiretroviral Strategies Versus a Standard PI-Containing Regimen, Final 48-Week Data (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Two Studies Shed Light on Development of d4T Resistance (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Epidemiologic Surveillance of HIV Resistance From 1994 to 1999; Increasing Frequency of Naive Patient Mutants (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Transmission of Drug-Resistant HIV-1 in San Francisco (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Low Frequency of Genotypic Resistance Markers in Therapy-Naive HIV+ Adolescents (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Research Updates on DPC 083, DPC 961 and DAPD (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Symposium: Management of Drug Resistance (July 10, 2000)
In The XIII International AIDS Conference, from The Body PRO
- 4th International Workshop on HIV Drug Resistance and Treatment Strategies (June 12 - 16, 2000)
In The 4th International Workshop on HIV Drug Resistance and Treatment Strategies, from The Body PRO
- Prevalence of Drug Resistance High (June 16, 2000)
From Canadian AIDS Treatment Information Exchange
- Measuring the Replicative Fitness of Recombinant HIV-1 Vectors Expressing Protease and Reverse Transcriptase Derived From Patient Viruses (January 31, 2000)
From Seattle Treatment Education Project
- Phenotypic Resistance Testing Significantly Improves Response to Therapy: A Randomized Trial (VIRA 3001) (January 31, 2000)
From Seattle Treatment Education Project
- Reduced Susceptibility to NRTI Is Associated With NNRTI Hypersensitivity in Virus From HIV-1-Infected Patients (January 31, 2000)
From Seattle Treatment Education Project
- Selection of Antiretroviral Resistance in the Latent Reservoir of Human Immunodeficiency Virus Type 1 During Successful Therapy (January 31, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Multdrug-Resistant HIV and Primary Infection: A New Threat to At-Risk Individuals, and a New Challenge for Care Providers (October 1999)
In HIV Newsline, from San Francisco General Hospital
- Chemokines and HIV Coreceptors: Opening Doors to New Anti-HIV Strategies (May 25, 1999)
From U.S. National Institute of Allergy and Infectious Diseases
- Drug Failure and Other Pleasant Surprises (Spring 1999)
In Notes From the Underground, from PWA Health Group
- High Frequency of Antiretroviral Drug Resistance in HIV-1 From Recently Infected Therapy Naive Individuals (February 4, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Selection of Protease Resistance Mutations in Semen (February 4, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Spectrum and Frequency of Reduced Antiretroviral Drug Susceptibility With Primary HIV Infection in the United States (February 4, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Mutations in the Reverse Transcriptase Genome of HIV I Isolates Derived from Subjects Treated with Didanosine and Stavudine in Combination (February 1, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Reverse Transcriptase Genotype After Multiple, Sequential Nucleoside Analog Drugs and Their Response to HAART and ACTG 364 (February 1, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Multiple Nucleoside Analogue Resistance Mutations Confer Cross-Resistance to Abacavir (February 1, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Resistance Risk
- Regimens With Boosted Protease Inhibitors Are the Most Resistance-Proof, Study Finds (May 22, 2008)
In The Journal of Infectious Diseases
- Drug Use During Sex May Make Infection With Drug-Resistant HIV More Likely (May 20, 2008)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Consequences of Non-Adherence Worse in African-Americans than White People (December 16, 2007)
From aidsmap.com
- First-Line Triple-Combination Antiretroviral Therapy Provides Long-Term Protection Against AIDS-Related Illnesses, Study Says (December 10, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug-Resistant HIV Transmission Is Falling Steadily in United Kingdom (May 1, 2007)
From aidsmap.com
- Emergence of Drug Resistance and First-Line Combination Therapy in the Swiss HIV Cohort Study (February 26, 2007)
To view original study poster, click here (PDF).
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- HIV Drug Resistance Common Among Recently Infected MSM: An Interview With Susan H. Eshleman, M.D., Ph.D., Johns Hopkins University (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- More Than 10% of U.S. Patients in 11 U.S. States With Either Newly or Recently Acquired HIV May Harbor Resistant Virus (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Incidence of Multidrug-Resistant Virus Appears to Be Declining in the HAART Era (November 14, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- Higher Degree of Medication "Forgiveness" in Use of Boosted Protease Inhibitors (August 15, 2006)
In The XVI International AIDS Conference
- HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO
- More Sensitive Drug-Resistance Tests Yield Higher Rates of Multidrug Resistance in Treatment-Naive Patients (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Transmission of Multidrug-Resistant HIV Will Not Become More Frequent in United Kingdom Through 2010, Statistical Model Suggests (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- Crystal Methamphetamine Use and Antiretroviral Drug Resistance: A Pilot Study of Behavioral and Clinical Correlates (October 2005)
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- HIV JournalView: Persistent, Low-Level Viremia May Breed Resistance (September 2005)
Whether treatment should be switched in viremic patients depends on the regimen and the viral load level, a new study suggests.
From The Body PRO
- NNRTIs Have a Greater Risk of Resistance Than PIs When Used in Regimens After Treatment Break (August 26, 2005)
From aidsmap.com
Resistance Testing
- Abacavir Hypersensitivity Test Could Be Combined With Drug Resistance Test: Study (June 4, 2007)
From aidsmap.com
- HIV Test May Show Which Drugs Work Best (January 8, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Resistance Testing Can Level the Playing Field for People Starting Treatment, Study Says (May 4, 2006)
From aidsmap.com
- More Sensitive Drug-Resistance Tests Yield Higher Rates of Multidrug Resistance in Treatment-Naive Patients (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Small Study Suggests Genotypic Resistance Tests Maintain Accuracy Even When Viral Load Is Below 1,000 (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Drug Resistance Testing in Treatment-Naive Patients Is Cost-Effective, May Extend Lives, Study Says (September 26, 2005)
From Infectious Diseases Society of America
- Antivirogram vs. PhenoSense Assays (April 2005)
The two differ significantly for some NRTIs, but not for NNRTIs or protease inhibitors, a study finds.
From The Body PRO
- Drug Resistance as Measured by Single vs. Multiple Genotypic Tests Over Time (April 2005)
A study finds benefits to retaining all of a patient's resistance test results and complete treatment history.
From The Body PRO
- Little Difference Between Resistance Testing Methods in Treatment-Experienced Patients (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Using Genotypic Inhibitory Quotient to Measure Response to Boosted-Amprenavir Regimen (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Prediction of NRTI Options by Linking Reverse Transcriptase Genotype to Phenotypic Breakpoints (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Research From the 42nd ICAAC: Resistance Tests Compared; Amprenavir Is Guinea Pig (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Genotyping Less Effective at Predicting Effective Regimens in Children (October 4, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Digging Deeper at the Resistance Workshop (August 14, 2002)
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society
- Antiretroviral-Drug Resistance Among Patients Recently Infected With HIV (August 8, 2002)
Greater primary resistance necessitates earlier drug-resistance testing, researchers say.
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- The GUESS Study: An International Evaluation of the Accuracy, Precision and Consistency of Expert HIV-1 Genotype Interpretation (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
- The ENVA-3 World Wide Evaluation Study Shows Extensive Differences in Interpretation on HIV-1 Genotype Analysis (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- The Role of Resistance Testing in an Inner-City Population (Fall 2001)
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
|
|
